Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 19

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 19
---
 product candidates and other programs as we advance them through clinical development;                |

| · | the number and development requirements of product candidates that we may pursue; |

| · | the costs, timing, and outcome of regulatory review of our product candidates; |

| · | the timing and amount of our milestone and royalty payments to InnoBation under the CD47 License; |

| · | the costs and timing of future commercialization activities, including product manufacturing, marketing, 
 sales, and distributions, for any of our product candidates for which we receive marketing approval;     |

| · | the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing 
 our intellectual property rights and defending any intellectual property-related claims;                 |

| · | the revenue, if any, received from sales of our product candidates for which we receive marketing approval; 
 and                                                                                                         |

| · | the costs of operating as a public company. |

Identifying
potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive, and uncertain process
that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve
product sales. In addition, our product candidate, if approved, may not achieve commercial success. Our commercial revenues, if any, will
be derived from sales of our product candidates that we do not expect to be commercially available in the near term, if at all. Accordingly,
we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be
available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, the terms of these equity securities or this debt may restrict our ability to operate. Any future debt financing and
equity financing, if available, may involve covenants limiting and restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures, entering into profit-sharing or other arrangements or declaring dividends. If we raise additional
funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required
to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses
on terms that may not be favorable to us. If we are unable to raise capital when needed or on acceptable terms, we could be forced to
delay, reduce or eliminate our research and development programs or future